

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LYBVAVDBV Cycles 3-8 (DOXOrubicin, vinBLAStine, and dacarbazine)

Page 1 of 2

DOCTOR'S ORDERS	Ht	_cm V	Vt	kg	BSA	m²
REMINDER: Please ensure drug allergies a	and previous bleomyci	n are dod	cumented or	n the A	llergy & Aler	t Form
DATE:	To be given:			Сус	le #:	
Date of Previous Cycle:						
☐ Delay treatment week(s☐ CBC & Diff, platelets day of treatmen						
May proceed with Day 1 doses as written if within 96 hours ANC greater than or equal to 0.6 x 10 9/L						
Dose modification for: Hematology Proceed with treatment based on blood						
PREMEDICATIONS: Patient to take own se	upply. RN/Pharmacist to	o confirm				
dexamethasone ☐ 8 mg or ☐ 12 mg (s and select ONE of the following:	select one) PO 30 to 6	0 minute	es prior to tr	eatmer	nt	
aprepitant 125 mg PO 30 to 60 minutes prior to treatment						
ondansetron 8 mg PO 30 to 60 minutes prior to treatment						
netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment						
If required after Cycle 1 due to prior infusion hydrocortisone 100 mg IV prior to etc. diphenhydrAMINE 50 mg IV prior to etc.	oposide					
Other:						
Have Hypersensitivity Reaction Tray and Protocol Available						
CHEMOTHERAPY: Note: Patients should be on filgrastim as per protocol. RN to confirm.						
DOXOrubicin 25 mg/m² x BSA =% = Dose Modification:% = IV push on Day 1 and Day 15	mg mg/m² x BS	6A =	r	ng		
vinBLAStine 6 mg/m ² x BSA =	mg					
☐ Dose Modification:% =	mg/m² x BSA =		mg			
dacarbazine 375 mg/m ² x BSA = IV in 250 to 500 mL NS over 1 to 2 hours						
If cardiac dysfunction: Omit DOXOrubicin. Give etoposide 25 mg/m² x BSA =mg □ Dose Modification:% =mg/m² x BSA =mg IV in 250 to 500 mL (non-DEHP bag) NS over 45 minutes on Day 1 and Day 15 (use non-DEHP tubing with in-line filter), AND etoposide 50 mg/m² x BSA x (%) =mg PO on Days 2 and 3 and Days 16 and 17 (Round dose to nearest 50 mg)						
If total bilirubin greater than 85 microm	ol/L: Omit DOXOrub	icin.				
Give cyclophosphamide 375 mg/m² x B: Dose Modification: % = _ IV in 100 to 250 mL NS over 20 minutes	SA =n mg/m² x BS	ng SA =		ng		
	o to i nour on Day I c	a Day		1	CHATUR	••
DOCTOR'S SIGNATURE:					SIGNATUR	· ·
				\ .	JC:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LYBVAVDBV Cycles 3-8 (DOXOrubicin, vinBLAStine, and dacarbazine)

Page 2 of 2

DATE:						
EMERGENCY DRUGS FOR MANAGEMENT OF ETOPOSIDE TOXICITY:						
hydrocortisone 100 mg IV prn / diphenhydrAMINE 50 mg IV prn						
RETURN APPOINTMENT ORDERS						
Return in <u>four</u> weeks for Doctor and Cycle (for DOXOrubicin, vinBLAStine, and dacarbazine). Book chemo on Days 1 and 15						
Return in <u>four</u> weeks for Doctor and Cycle 9 (for brentuximab vedotin). Book chemo on Day 1						
Last Cycle. Return in week(s)						
CBC & Diff, platelets prior to Day 1 of each cycle of treatment						
If clinically indicated:						
☐ total bilirubin ☐ ALT ☐ creatinine						
☐ Other tests:						
☐ Consults:						
☐ See general orders sheet for additional requests.						
DOCTOR'S SIGNATURE:	SIGNATURE:					
	UC:					